During this year´s AACR Annual Meeting, Washington DC, April 6 -10, ecancer caught up with VHIO´s Laura Soucek, PI of the Mouse Models of Cancer Therapies Group, to discuss her group´s pioneering work on Myc inihibition in pre-clinical mouse models.
Related Posts
Science comes to VHIO: 23 January 2012
Marking the second in the prestigious series of talks: VHIO Meet the Editors, Science´s Paula Kiberstis, Senior Editor, cancer research, will be joining us to deliver what promises to be a highly insightful presentation on Demystifying Science.
01 Dec 2011
Fero Community´s annual fundraising gala dinner and award ceremony: a record-breaking celebration
Celebrated last week and returning to the stunning Oval Room of Catalonia´s National Museum of Art (MNAC), Fero´s community joined…
15 May 2017
An independent nationwide evaluation ranks Vall d´Hebron´s Medical Oncology Service top of the leaderboard for second consecutive year
Barcelona, 18 November 2015.-According to a second independent, annual benchmark evaluation of the Spanish healthcare sector, Monitor de Reputación Sanitaria…
18 Nov 2015
Cancer Core Europe proudly announces the appointment of Professor Fabien Calvo as Chief Scientific officer
Source: Gustave Roussy Cancer Campus Grand Paris An appointment reflecting the ambitions of Cancer Core Europe As of December…
16 Dec 2014
José Baselga wins the Jaume I prize on Medical Research
VHIO Scientific Manager is a pioneer in translational research
07 Sep 2010
Eribulin as an effective second-line therapy in patients with advanced breast cancer
The results of a clinical trial led by researchers at VHIO have established eribulin as effective therapy in patients with…
30 Jan 2015
Abstract Submission & Registration Open: VHIO/Fritz-Bender-Foundation Intl. Symposium: Progress Towards Individualized Cancer Treatments, 07 – 09 November 2013
Marking the 17th International Symposium in the annual series of prestigious meetings organized by the Fritz-Bender Foundation, we are delighted…
31 Jul 2013
VHIO collaborates in European, multi-center study aimed at reducing side-effects of radiotherapy
Supported by the European Commission´s 7th Framework Programme of Research and Development, and coordinated by Catharine West, University of Manchester,…
13 Jan 2014
Translational cancer research for tomorrow´s targeted therapy: the barometer of VHIO success
In a joint ecancermedicalscience interview filmed at ASCO 2011 in Chicago, José Baselga and Josep Tabernero describe the early beginnings…
04 Jul 2011
The promise of an active surveillance strategy in patients with metastatic renal cancer
VHIO co-collaborates in a prospective, phase II clinical trial studying patients with metastatic renal-cell carcinoma Findings evidenced active surveillance as…
13 Sep 2016
ecancer catches up with VHIO´s Paolo Nuciforo during the 2015 WIN Symposium
During last month´s WIN – Worldwide Innovative Networking in personalized cancer medicine, Symposium, June 29 – 30, Paris, France, ecancer…
07 Jul 2015
Study describes phenomenon of resistance to novel therapy for advanced lung cancer
• Resistance to targeted therapies for lung cancer, the most common cancer worldwide, represents one of the major limitations in…
05 May 2015
3D Organoids: unmasking mechanisms of resistance and accelerating precision medicine against metastatic colorectal cancer
In addition to marking the launch of World Cancer Research Day, last week´s AECC Institutional Act presided by Her Majesty…
05 Oct 2016
Josep Tabernero: 1 of the 11 Catalonia-based candidates for DIARIO MEDICO´s Top 25 ambassadors of biomedicine and healthcare in Spain – VOTING NOW OPEN
In celebration of its 25th Anniversary, DIARIO MEDICO – one of Spain´s leading medical periodicals, has just opened a poll…
04 Jul 2017
